Literature DB >> 34723628

In Vitro Activity of Pretomanid against Nontuberculous Mycobacteria.

Huiwen Zheng1, Yiting Wang2, Wencong He2, Feina Li1, Hui Xia2, Bing Zhao2, Shengfen Wang2, Chen Shen1, Yanlin Zhao2.   

Abstract

Entities:  

Keywords:  nontuberculous mycobacterium; pretomanid

Mesh：

Substances：

Year:  2021        PMID： 34723628      PMCID： PMC8765262          DOI： 10.1128/AAC.01810-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


× No keyword cloud information.
  7 in total

1.  In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China.

Authors:  Xia Yu; XiaoPan Gao; Chenghai Li; Jingjing Luo; Shuan Wen; Tingting Zhang; Yifeng Ma; Lingling Dong; Fen Wang; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.

Authors:  Dae Hun Kim; Byung Woo Jhun; Seong Mi Moon; Su-Young Kim; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  In Vitro Activity of Rifamycin Derivatives against Nontuberculous Mycobacteria, including Macrolide-/Amikacin-Resistant Clinical Isolates.

Authors:  Dae Hun Kim; Su-Young Kim; Hee Jae Huh; Nam Yong Lee; Won-Jung Koh; Byung Woo Jhun
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

4.  In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

5.  Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.

Authors:  Cheon Tae Kim; Tae-Ok Kim; Hong-Joon Shin; Young Chun Ko; Yeong Hun Choe; Hak-Ryul Kim; Yong-Soo Kwon
Journal:  Eur Respir J       Date:  2018-03-22       Impact factor: 16.671

6.  High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.

Authors:  Norbert Ndjeka; Kathryn Schnippel; Iqbal Master; Graeme Meintjes; Gary Maartens; Rodolfo Romero; Xavier Padanilam; Martin Enwerem; Sunitha Chotoo; Nalini Singh; Jennifer Hughes; Ebrahim Variava; Hannetjie Ferreira; Julian Te Riele; Nazir Ismail; Erika Mohr; Nonkqubela Bantubani; Francesca Conradie
Journal:  Eur Respir J       Date:  2018-12-20       Impact factor: 16.671

7.  Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis.

Authors:  Fuzhen Zhang; Shanshan Li; Shuan Wen; Tingting Zhang; Yuanyuan Shang; Fengmin Huo; Yi Xue; Ling Li; Yu Pang
Journal:  Infect Drug Resist       Date:  2020-03-11       Impact factor: 4.003
  7 in total
  1 in total

Review 1.  Uncovering interactions between mycobacterial respiratory complexes to target drug-resistant Mycobacterium tuberculosis.

Authors:  Matthew B McNeil; Chen-Yi Cheung; Natalie J E Waller; Cara Adolph; Cassandra L Chapman; Noon E J Seeto; William Jowsey; Zhengqiu Li; H M Adnan Hameed; Tianyu Zhang; Gregory M Cook
Journal:  Front Cell Infect Microbiol       Date:  2022-08-24       Impact factor: 6.073
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.